EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discordance in genotypic and phenotypic drug susceptibility results: time to reconsider critical concentration of rifampicin

Arti Shrivas, Sarman Singh iD, Jitendra Singh, Prem Shankar, Payal Soni, Syed Beenish Rufai, Anand Maurya, Shashank Purwar

Microbiology Spectrum · 2025

DOI: 10.1128/spectrum.02236-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2025. Verfasst von Arti Shrivas und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, All India Institute of Medical Sciences, Bhopal, India. Hauptthemen laut MEDLINE: Rifampin, Mycobacterium tuberculosis, Antitubercular Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Indian Council of Medical Research (ICMR).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The objective of this study is to correlate rpoB mutations found on the new-generation sequencing (NGS) in Mycobacterium tuberculosis (MTB) isolates with minimum inhibitory concentrations (MICs) to the rifampicin (RIF). We assessed the minimum inhibitory concentrations for 151 archived clinical MTB isolates that were determined phenotypically susceptible to RIF (101; 66.89%), and the remaining 50 (50; 33.11%) were resistant to RIF by BACTEC MGIT SIRE DST. MIC values were determined using the colorimetric redox indicator (Resazurin/REMA) method, and results were correlated with rpoB gene mutations associated with rifampicin resistance found. Comparing the MIC and critical concentration, we found that 15 of these 101 (14.85%) isolates were misclassified by MGIT-960 as sensitive at standard critical concentration (1.0 µg/mL) though these were found to have low-level RIF resistance by CRI assay (MIC 0.50 to 1.0µg/mL) and NGS. We found that all 15 isolates contained non-synonymous mutations, the commonest being the Ile572Phe (7, 46.66%), followed by Leu533Pro (3, 20.0%), His526Leu (2, 13.33%), His526Asn+Ile572 Phe (1), Asp516Tyr (1), and Leu533Pro+Pro564 Arg (1). These mutations are reported to confer low-level RIF resistance. But we did not find any mutation at MIC ≤0.25 µg/mL. We found that a significant number of MTB isolates have phenotypic and genotypic discordance. Taking 1.0 µg/mL of rifampicin as a critical concentration, isolates from approximately 15% of patients are misidentified as susceptible to rifampicin, even when these strains carry low-level drug resistance-conferring mutations and have the potential to develop clinical multidrug-resistant tuberculosis. IMPORTANCE Tuberculosis (TB) remains a leading cause of morbidity and mortality worldwide, killing millions every year. The emergence of multidrug-resistant and extensively drug-resistant TB forms poses a challenge to the TB control programs. In the past few decades, several molecular tests for rapid detection and drug resistance determination have been developed. But these can miss the genetic mutations that confer low-level resistance to rifampicin (RIF), a critical constituent for treating drug-susceptible TB. On the other hand, for the phenotypic methods, a cutoff value is fixed, known as critical concentration (CC). The current WHO-endorsed CC for rifampicin is 1.0 μg/mL in liquid culture for confirmation of drug resistance; because of that in this system too, low-level RIF resistance may not be correctly identified. Therefore, it is important that either the CC for phenotypic methods is lowered or the specific mutations are included in the molecular tests. This study provides important insights in that direction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RifampinMycobacterium tuberculosisAntitubercular AgentsMicrobial Sensitivity TestsHumansPhenotypeGenotypeDNA-Directed RNA PolymerasesBacterial ProteinsMutationDrug Resistance, BacterialHigh-Throughput Nucleotide SequencingTuberculosis

Stichwörter der Autor:innen

critical concentrationminimum inhibitory concentrationmutationsrifampicintuberculosis

Substanzen

RifampinDNA-Directed RNA PolymerasesBacterial ProteinsAntitubercular AgentsrpoB protein, Mycobacterium tuberculosis

Autor:innen und Institutionen

  • Department of Microbiology, All India Institute of Medical Sciences, Bhopal, India.
  • Aarupadai Veedu Medical College, Vinayaka Mission's Research Foundation, Pondicherry, India.
  • Translational Medicine Centre, All India Institute of Medical Sciences, Bhopal, India.

ORCID-Profile: Sarman Singh

Förderung

  • Indian Council of Medical Research (ICMR)

Zitieren

APA

Shrivas, A., Singh, S., Singh, J., Shankar, P., Soni, P., Rufai, S. B., Maurya, A., & Purwar, S. (2025). Discordance in genotypic and phenotypic drug susceptibility results: time to reconsider critical concentration of rifampicin. Microbiology Spectrum. https://doi.org/10.1128/spectrum.02236-24

Vancouver

Shrivas A, Singh S, Singh J, Shankar P, Soni P, Rufai SB, et al. Discordance in genotypic and phenotypic drug susceptibility results: time to reconsider critical concentration of rifampicin. Microbiology Spectrum. 2025. doi:10.1128/spectrum.02236-24

BibTeX
@article{Shrivas2025,
  author = {Shrivas, Arti and Singh, Sarman and Singh, Jitendra and Shankar, Prem and Soni, Payal and Rufai, Syed Beenish and Maurya, Anand and Purwar, Shashank},
  title = {Discordance in genotypic and phenotypic drug susceptibility results: time to reconsider critical concentration of rifampicin},
  journal = {Microbiology Spectrum},
  year = {2025},
  doi = {10.1128/spectrum.02236-24}
}
Kostenlos starten →